Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN D 24 HOUR versus HISTAFED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN D 24 HOUR versus HISTAFED.
CLARITIN-D 24 HOUR vs HISTAFED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonism; pseudoephedrine is a sympathomimetic amine that acts as an alpha-adrenergic agonist, causing vasoconstriction in the nasal mucosa.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
1 tablet (10 mg loratadine/240 mg pseudoephedrine) orally once daily
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
None Documented
None Documented
Loratadine: 8-11 hours (mean 10.6 ± 4.6 h); desloratadine: 17-24 hours (mean 19.4 ± 7.5 h). Terminal half-life is prolonged in chronic hepatic impairment (mean 37 h for loratadine, 47 h for desloratadine).
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
Renal (40%) as unchanged drug and metabolites; biliary/fecal (minor). Approximately 27% of loratadine and 40% of desloratadine are excreted in urine over 10 days.
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine/Decongestant Combination